background: adherence to prescribed therapeutic regimen is an important element of self-care behaviors in cardiac patients. awareness of disease may play an important role in patient adherence. thus, this study was conducted to examine the relationship between awareness of the disease and adherence to therapeutic regimen among cardiac patients admitted to selected hospitals in mashhad, iran. me...

conclusions if such a regimen is approved, it would be a breakthrough in the treatment of hcv in subjects with hemoglobinopathy. more prospective, randomized control trial studies are needed to investigate the efficacy and safety profile of such a regimen. case presentation we described a 16- year-old male patient with sickle-thalassemia who was infected with a hcv. treatment was started with s...

BACKGROUND To investigate the reasons and risk factors for modification of the first combined antiretroviral therapy (cART) currently used for HIV infected patients who were treatment naïve in Shanghai China. METHODS Making a retrospective observational research on treatment naïve patients with HIV infection who initiated cART during the period of September 1st 2005---December 1st 2013. The d...

Laboratory interactions (Quality of Evidence: high; no clinical significance) • Cobicistat (Stribild®, Tybost®), rilpivirine (Edurant®, Complera®) and dolutegravir (Tivicay®) containing regimens will increase serum creatinine by approximately 7-15 μmol/L during the first 4 weeks of treatment initiation due to inhibition of renal creatinine secretion. This does not reflect an actual decrease in ...

OBJECTIVES To compare a new low-dose warfarin induction regimen with the Fennerty regimen in elderly inpatients. DESIGN Age-stratified, randomized prospective study. SUBJECTS 120 age-stratified elderly inpatients. INTERVENTIONS Each patient was randomized to either the new induction regimen or to a modified Fennerty regimen. MAIN OUTCOMES MEASURES Days to therapeutic International Norma...

Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil-based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI...

BACKGROUND We previously reported that weekly treatment with docetaxel alone is useful for and well tolerated by patients with hormone-refractory prostate cancer (HRPC). Here, we compare it with the regimen of docetaxel once every 3 weeks (q3w) plus daily prednisone (PSL) based on a TAX 327 trial in order to clarify the efficacy and toxicity of docetaxel regimens in Japan. METHODS Thirty-two ...